11-02/03 :: February / March 2011
nanotimes
Companies Facts
presented include results of a survey of over 100 Ob- stetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to tre- at a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).
With the Solid Injection by Air Stream (SIA) method from Bayer MaterialScience, the solids are transported in a gas stream and only injected into the mixing chamber during the blending phase. This method opens up entirely new possibilities for the use of composite materials, regardless of whether they are hard or soft, or if the polyurethane is a solid or a foam. One possible area of application is adding flame retardants to polyurethane parts, which is required for a variety of applications. © BMS
There are currently no FDA-approved therapeutic treatment options for women with HSDD. A signifi- cant number of physicians (over 90 percent) reported that they prescribe off-label testosterone for women to treat FSD, however, these physicians are dissa- tisfied with the non-FDA approved, off-label alter- natives. The physicians indicated that they hear an average of 37 unsolicited inquiries per month from women regarding sexual dysfunction. Nationally, it is estimated that 4.1 million off-label testosterone prescriptions are filled annually.
http://www.biosantepharma.com
Gund Investment Corporation and existing investors Battelle Ventures, Innovation Valley Partners and KT Venture Group joining the round.
Furthermore, BioNanomatrix introduced the nano- Analyzer 1000 System at the 2010 Annual Meeting of the American Society of Human Genetics last Novem- ber and said that the company “has already placed a number of systems with early-access users.”
http://www.bionanomatrix.com
B
ioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company developing products
for the treatment of female sexual health, presented critical female sexual dysfunction market data at the ISSWSH (The International Society for the Study of Women’s Sexual Health) annual meeting. The data
C
arl Zeiss has been awarded a $22.6 million contract to develop certain nano manufacturing
and imaging applications based on its revolutionary ORION™ Gas Field Ion Source (GFIS) technology. The contract was awarded to US-based Carl Zeiss NTS, LLC by the Intelligence Advanced Research Projects Activity (IARPA) under the Circuit Analysis Tool (CAT) program.
The CAT program is geared towards addressing chal- lenges in nano manufacturing and imaging pertaining to circuit analysis for which existing techniques have no clear evolutionary path to the 22nm node and beyond. The nano manufacturing thrust of the CAT program is focused on the modification of the electri- cal behavior of an integrated circuit through the use of precise deposition and removal techniques that can cut and/or create new connections. The GFIS
21
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95